Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion

Transplantation

Volumn 78, Issue 10, 2004, Pages 1515-1522

  Hahn, Theresa ^a   Alam, Arif Raza ^a   Lawrence, David ^a   Ford, LaurieAnn ^a   Baer, Maria R ^a   Bambach, Barbara ^a   Bernstein, Zale P ^a   Czuczman, Myron S ^a   Silva, Joaquin ^a   Slack, James L ^a   Wetzler, Meir ^a   Becker, Joanne ^a   McCarthy Jr , Philip L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Allogeneic BMT associated thrombotic microangiopathy; Regimen related toxicity

Indexed keywords

ACICLOVIR; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ENOXAPARIN; ETOPOSIDE; FLUCONAZOLE; HEPARIN; IMMUNOGLOBULIN; IMMUNOPHILIN; KETOCONAZOLE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYELOABLATIVE AGENT; OKT 3; PROSTAGLANDIN E1; STEROID; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOADSORPTION; LIVING DONOR; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; STANDARD; T LYMPHOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTE DEPLETION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISK FACTORS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 9244262979     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000141363.81600.0D     Document Type: Article

References (45)

1. George JN, Li X, McMinn JR, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: A diagnostic dilemma. Transfusion 2004; 44: 294.
2. Moake JL. Thrombotic thrombocytopenic purpura. Thromb Haemost 1995; 74: 240.
3. Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996; 56: 191.
4. Shepard KV, Bukowski RM. The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions and plasma exchange. Semin Hematol 1987; 24: 178.
5. Kwaan HC, Soff GA. Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997; 34: 159.
6. Winslow GA, Nelson EW. Thrombotic thrombocytopenic purpura: Indications for and results of splenectomy. Am J Surg 1995; 170: 558.
7. Zeigler ZR, Shadduck RK, Nath R, Andrews DF. Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplant associated thrombotic microangiopathy. Bone Marrow Transplant 1996; 17: 81.
8. Guinan EC, Tarbell NJ, Neimeyer CM, et al. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood 1988; 72: 451.
9. Byrnes JJ, Hussein AM. Thrombotic microangiopathic syndromes after bone marrow transplantation. Cancer Invest 1996; 14: 151.
10. Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001; 113: 58.
11. Ruutu T, Hermans J, Niederwieser D, et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: A survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 1112.
12. Paquette RL, Tran L, Landaw EM. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant 1998; 22: 351.
13. Roy V, Rizvi MA, Vesely SK, et al. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: An analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27: 641.
14. Zeigler ZR, Shadduck RK, Nemunaitis J, et al. Bone marrow transplant-associated thrombotic microangiopathy: A case series. Bone Marrow Transplant 1995; 15: 247.
15. Rabinowe SN, Soiffer RJ, Tarbell NJ, et al. Hemolytic uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 1991; 77: 1837.
16. Sarode R, McFarland JG, Flomenberg N, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995; 16: 271.
17. Arai S, Allan C, Streiff M, et al. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J 2001; 2: 292.
18. Brown RA, Wolff SN, Fay JW, et al. High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: A study by the North American Marrow Transplantation Group. Blood 1995; 85: 1391.
19. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347.
20. Mulder PO, De Vries EG, Koops HS, et al. Chemotherapy with maximally tolerable doses of VP 16 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol 1988; 24: 675.
21. Helenglass G, Powles RL, McElwain TJ, et al. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplant 1988; 3: 21.
22. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 1991; 77: 1660.
23. Thomas ED, Storb R, Fefer A, et al. Aplastic anaemia treated by marrow transplantation. Lancet 1972; 1: 284.
24. Alidina A, Lawrence D, Ford LA, et al. Thiotepa associated cardiomyopathy during blood or marrow transplantation: Associated with female sex and cardiac risk factors. Biol Blood Marrow Transplant 1999; 5: 322.
25. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382.
26. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: Reduced-in tensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631.
27. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941.
28. Shepherd JD, Shore TB, Reece DE, et al. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3: 553.
29. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisone for prophylaxis for acute graft-versus-host disease. N Engl J Med 1993; 329: 1225.
30. Alam A, Baer MR, Bernstein S, et al. Phase II clinical trial of OKT3 for acute graft-versus-host disease (GVHD) prophylaxis in allogeneic bone marrow transplantation (alio BMT) [abstract]. Blood 1997; 90: 102a.
31. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838.
32. Cahn JY, Herve P, Flesch M, et al. Marrow transplantation from HLA non-identical family donors for the treatment of leukemia: A pilot study of 15 patients using additional immunosuppression and T-cell depletion. Br J Haematol 1988; 69: 345.
33. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A matched sibling donors. Transplantation 1974; 18: 295.
34. Simon M, Hahn T, Ford LA, et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: Possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001; 27: 627.
35. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393.
36. Obrador GT, Zeigler ZR, Shadduck RK, et al. Effectiveness of cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura. Am J Hematol 1993; 42: 217.
37. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993; 12: 737.
38. Cox DR, Oakes D. Analysis of survival data. New York, Chapman & Hall 1984, pp 1-98.
39. Lee PM. Bayesian statistics: An introduction. New York, Halsted Press 1989, pp 80-86.
40. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495.
41. Zeigler ZR, Kelton JG, Moore JC, et al. Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 1999; 24: 641.
42. Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed AGVHD after HLA identical bone marrow transplantation. Blood 1989; 73: 2018.
43. Uderzo C, Fumagalli M, De Lorenzo P, et al. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1005.
44. Daly AS, Hasegawa WS, Lipton JH, et al. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apheresis Sci 2002; 27: 3.
45. Kalhs P, Brugger S, Schwarzinger I, et al. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis. Transplantation 1995; 60: 949.